Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin in Systemic Lupus Erythematosus
NCT03953261Phase 2Terminated
- Sponsor
- Loma Linda University
- Start
- Sep 2019
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial (2 arms), sponsored by Loma Linda University. Primary endpoint: Systemic Lupus Erythematosus Disease Activity Index at 90 days. Started Sep 2019; status: terminated.
Beyond the preview
Go deeper on NCT03953261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953261.